Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524A in primary hypercholesterolemia or mixed hyperlipidemia
NCT00536510Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of laropiprant, niacin in hypercholesterolemia, hyperlipidemia, sponsored by Merck & Co.. Started Apr 2007; status: completed.
02
Drugs
laropiprantniacin
03
Conditions
hypercholesterolemiahyperlipidemia
Beyond the preview
Go deeper on NCT00536510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00536510.